Long Noncoding RNA MALAT1 Regulates the Progression of Atherosclerosis by miR-330-5p/NF-κB Signal Pathway

Zhifeng Shi1, Zhixiong Zheng, Xiaodan Lin

  • 1Department of Neurology, MinDong Hospital of Ningde City, Fuan City, Fujian Province, China.

Insights

Long non-coding RNA MALAT1 promotes atherosclerosis by sponging miR-330-5p, activating the NF-κB pathway. This reveals MALAT1 as a potential biomarker for atherosclerosis diagnosis and treatment.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • RNA Biology

Background:

  • Atherosclerosis (AS) is a complex cardiovascular disease.
  • The role of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in AS pathogenesis is not fully understood.
  • Investigating the molecular mechanisms underlying MALAT1's involvement in AS is crucial.

Purpose of the Study:

  • To elucidate the mechanism by which MALAT1 influences atherosclerosis.
  • To determine the relationship between MALAT1, miR-330-5p, and the NF-κB pathway in AS.
  • To evaluate MALAT1 as a potential biomarker for AS.

Main Methods:

  • Quantitative real-time PCR to measure MALAT1 and miR-330-5p expression.
  • Western blot to analyze key proteins and signaling pathways (NF-κB).
  • In vitro assays (foam cell models) and in vivo AS mouse models were utilized.

Main Results:

  • MALAT1 was upregulated, and miR-330-5p was downregulated in foam cells.
  • MALAT1 depletion reduced foam cell formation, apoptosis, and inflammation.
  • MALAT1 overexpression exacerbated inflammation in AS mice, mediated by sponging miR-330-5p and activating the NF-κB pathway.

Conclusions:

  • MALAT1 promotes AS pathogenesis by sponging miR-330-5p, thereby activating the NF-κB signaling pathway.
  • MALAT1 plays a significant role in the development and progression of atherosclerosis.
  • MALAT1 represents a potential novel biomarker for AS diagnosis.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.1K
Inflammation01:38

Inflammation

Overview
56.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
185
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
67